Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response
Authors
Stewart, A. R.Pickard, L.
Paranjape, E.
Perez, V. S.
Chowdhury, S.
Lustgarten, S.
Coma, S.
Pachter, J. A.
Carey, M. S.
DiMattia, G.
Badham, H. C.
Prout, T.
Parmar, M.
Mahmud, M.
Yap, C.
Krebs, Matthew G
Banerjee, S.
Banerji, U.
Affiliation
The Institute of Cancer Research, LondonIssue Date
2022
Metadata
Show full item recordCitation
Stewart AR, Pickard L, Paranjape E, Perez VS, Chowdhury S, Lustgarten S, et al. Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response. Cancer Research. 2022 Jun;82(12). PubMed PMID: WOS:000892509507142.Journal
Cancer ResearchDOI
10.1158/1538-7445.AM2022-3476Additional Links
https://dx.doi.org/10.1158/1538-7445.AM2022-3476Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2022-3476